| Name | Title | Contact Details |
|---|---|---|
Charles Sprinkle |
Vice President for Legal Affairs | Profile |
Yelena Trepetin |
General Counsel, Senior Associate | Profile |
Angela Wishon |
Vice President, Research Compliance and Administration | Profile |
Matthew Fowler |
Senior Vice President and Deputy General Counsel | Profile |
Russell Reynolds Associates (RRA) is a global leadership advisory and executive search firm founded in 1969 in New York City. Initially focused on financial services, RRA has expanded its expertise to various industries, including healthcare, consumer goods, technology, and industrial sectors. With 47 offices worldwide, the firm specializes in identifying and developing transformational leaders for public, private, and non-profit organizations. RRA offers a range of services, including executive search for C-suite and board roles, leadership advisory for succession planning and team effectiveness, and board advisory for governance and director recruitment. The firm utilizes proprietary assessment tools, such as the Leadership Span Assessment, to evaluate leadership capabilities. RRA serves a diverse clientele, including Fortune 500 companies and non-profits, and emphasizes a high-touch approach to address challenges like sustainability and digital transformation. With over 470 consultants across 26+ countries, RRA maintains a strong international presence and adapts to evolving leadership demands.
Continental Automotive Trading Italia Srl ha sede a Cinisello Balsamo (MI) e fa parte del Gruppo Continental, che con i marchi VDO, ATE e GALFER è tra i principali fornitori mondiali di elettronica e meccatronica per il settore automotive. Presso la sede di Cinisello Balsamo è presente anche un servizio di assistenza e formazione altamente qualificato. Continental Automotive Trading Italia Srl si avvale di una rete capillare di vendita estesa su tutto il territorio nazionale. VDO – Tachigrafi, Telematica e Servizi VDO è leader globale nel mercato delle soluzioni per tachigrafi. Il DTCO (tachigrafo digitale) di VDO e i suoi componenti offrono ad autisti, a gestori di flotte e autorità una soluzione conforme alla normativa, affidabile e tecnologicamente avanzata, che definisce gli standard per prestazioni allavanguardia, facilità dutilizzo e sicurezza dei dati. ATE Il marchio ATE si occupa di tutto ciò che riguarda i ricambi per freni, in particolare i componenti di usura ed idraulici per ricambi di qualità o per interventi di integrazione ed ottimizzazione finalizzati a un maggiore livello di sicurezza e divertimento alla guida. Ricerca ed evoluzione costanti, esperienze nelle grandi serie e tradizione negli sport motoristici rendono i nostri prodotti per la componentistica automotive fra i più venduti. GALFER Le pastiglie freno GALFER sono soluzioni di altissima qualità ottenute grazie a materiali di prima scelta, una lavorazione puntuale, una sofisticata logistica con una grande attenzione ai costi. Il Gruppo Continental Continental rappresenta uno dei principali fornitori mondiali del settore automotive. Come fornitore di sistemi frenanti, sistemi e componenti powertrain e chassis, soluzioni infotainment, elettronica del veicolo, pneumatici ed elastomeri tecnici, il Gruppo dà il proprio attivo contributo per la sicurezza di guida. Con un fatturato di 44 miliardi di Euro nel 2017, Continental attualmente impiega più di 238.000 persone in 61 Paesi.
ODP Business Solutions, LLC, an operating company of The ODP Corporation (NASDAQ:ODP), is a leading B2B provider of workplace and technology solutions, combining an extensive range of products and services with a national footprint and hundreds of experienced business advisors. As a trusted partner, ODP Business Solutions supports over 120,000 corporate clients with navigating the often complex needs of todays business environment. From accessing comprehensive solutions and strategic alliances, to supply chain innovation and robust digital platforms, ODP Business Solutions helps customers achieve business results across every industry. #ODPBusinessSolutions #workplacesolutions #technologysolutions #B2Bprovider
Estiatorio Milos is a renowned restaurant group founded in 1979 by Greek restaurateur Costas Spiliadis in Montreal. It is celebrated for its authentic Greek cuisine, emphasizing high-quality, fresh ingredients. With locations in major cities like New York, Athens, Las Vegas, Miami, London, Los Cabos, and Dubai, Milos offers refined dining experiences that prioritize simplicity and the art of sharing. The restaurant specializes in Mediterranean seafood, featuring fresh fish and shellfish sourced directly from Greek fishermen. Dishes are crafted to highlight natural flavors, often using artisanal ingredients like cold-pressed Koroneiki olive oil and seasonal vegetables. Milos is known for its warm hospitality and communal dining atmosphere, making it a favorite among discerning diners and culinary enthusiasts seeking an authentic taste of Greece.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.